Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering

被引:4
|
作者
Ducrey, Eloise [1 ,2 ,3 ]
Castrogiovanni, Cedric [3 ,4 ]
Meraldi, Patrick [3 ,4 ]
Nowak-Sliwinska, Patrycja [1 ,2 ,3 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, Fac Sci, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[2] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[3] Translat Res Ctr Oncohaematol, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[4] Univ Geneva, Dept Cell Physiol & Metab, Sch Med, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
基金
瑞士国家科学基金会;
关键词
Mitosis; Drug combination; Cancer; Centrosome clustering;
D O I
10.1007/s10495-021-01671-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitosis, under the control of the microtubule-based mitotic spindle, is an attractive target for anti-cancer treatments, as cancer cells undergo frequent and uncontrolled cell divisions. Microtubule targeting agents that disrupt mitosis or single molecule inhibitors of mitotic kinases or microtubule motors kill cancer cells with a high efficacy. These treatments have, nevertheless, severe disadvantages: they also target frequently dividing healthy tissues, such as the haematopoietic system, and they often lose their efficacy due to primary or acquired resistance mechanisms. An alternative target that has emerged in dividing cancer cells is their ability to "cluster" the poles of the mitotic spindle into a bipolar configuration. This mechanism is necessary for the specific survival of cancer cells that tend to form multipolar spindles due to the frequent presence of abnormal centrosome numbers or other spindle defects. Here we discuss the recent development of combinatorial treatments targeting spindle pole clustering that specifically target cancer cells bearing aberrant centrosome numbers and that have the potential to avoid resistance mechanism due their combinatorial nature.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [31] Tongue edema as an adverse drug reaction to low-dose olanzapine in a cancer patient receiving palliative care
    Moroni, Matteo
    Bruera, Eduardo
    PALLIATIVE & SUPPORTIVE CARE, 2024,
  • [32] Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug
    Curigliano, Giuseppe
    Balduzzi, Alessandra
    Goldhirsch, Aron
    Colleoni, Marco
    SUPPORTIVE CARE IN CANCER, 2008, 16 (03) : 313 - 314
  • [33] Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients
    Kono, Takashi
    Ueda, Tsutomu
    Takumida, Masaya
    Furuie, Hiromi
    Hamamoto, Takao
    Takeno, Sachio
    Hirakawa, Katsuhiro
    ACTA OTO-LARYNGOLOGICA, 2018, 138 (10) : 921 - 925
  • [34] Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines
    Lee, Sang-Cheol
    Cheong, Hee-Jeong
    Kim, Sook-Ja
    Yoon, Jina
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyoung
    Kim, Hyun Jung
    Bae, Sang Byung
    Kim, Chan-Kyu
    Lee, Namsu
    Lee, Kyu Taeg
    Park, Sung Kyu
    Hong, Dae Sik
    Park, Hee Sook
    Won, Jong-Ho
    ANTICANCER RESEARCH, 2011, 31 (10) : 3385 - 3394
  • [35] Low-dose epirubicin inhibits ezrin-mediated metastatic behavior of breast cancer cells
    Ma, Li
    Liu, Yue-Ping
    Geng, Cui-Zhi
    Xing, Ling-Xiao
    Zhang, Xiang-Hong
    TUMORI JOURNAL, 2011, 97 (03): : 400 - 405
  • [36] Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts
    Wang, Tingting
    Gao, Jing
    Yu, Jingwei
    Shen, Lin
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (05) : 505 - 513
  • [37] Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts
    Tingting Wang
    Jing Gao
    Jingwei Yu
    Lin Shen
    ChineseJournalofCancerResearch, 2013, 25 (05) : 505 - 513
  • [38] Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells
    Inamura, So
    Ito, Hideaki
    Taga, Minekatsu
    Tsuchiyama, Katsuki
    Hoshino, Hitomi
    Kobayashi, Motohiro
    Yokoyama, Osamu
    ANTICANCER RESEARCH, 2019, 39 (10) : 5417 - 5425
  • [39] Synergistic Cancer Growth-Inhibitory Effect of Emodin and Low-Dose Cisplatin on Gastric Cancer Cells In vitro
    Huang, Ling
    Wang, Xin-Bao
    Yu, Qi-Ming
    Luo, Qing-Ying
    Zhang, Zun-Zhen
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (08) : 1427 - 1434
  • [40] Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis
    Reiner, Teresita
    de las Pozas, Alicia
    Gomez, Lourdes A.
    Perez-Stable, Carlos
    CANCER LETTERS, 2009, 276 (01) : 21 - 31